Back

Timing of early recurrence predicts long-term outcomes after cryoballoon pulmonary vein isolation

12 April 2026 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Outcome of atrial fibrillation cryoablation Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Associate Professor Adil Baimbetov

Syzganovs National Scientific Center of Surgery, Almaty (Kazakhstan)

4 More presentations in this session

Presentation thumbnail
Comparative procedural outcomes of pulsed field, cryoballoon, and radiofrequency ablation for paroxysmal atrial fibrillation: a 15-year single-centre experience
Doctor N. Atan (Kuala Lumpur, MY)
Abstract Slides Video
Presentation thumbnail
Three-year follow-up of atrial fibrillation burden reduction after cryoballoon pulmonary vein isolation in early persistent atrial fibrillation: results from the COOL-PER trial
Doctor S. Han (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Single-shot ablation for AF: real-world procedural and one-year outcomes with the newly adopted PulseSelect PFA compared with cryoballoon from the 1STOP project
Professor G. Boriani (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Very high-power short-duration ablation vs. cryoballoon for paroxysmal atrial fibrillation: a prospective single-center study with one-year follow- up
Doctor D. Debreceni (Pecs, HU)
Abstract Slides Video

Access the full session

Session thumbnail
Outcome of atrial fibrillation cryoablation

The Event

Event poster

EHRA 2026

12 April - 14 April 2026
You may be interested in
thumbnail
Congress Presentation
Do we need a blanking period following atrial fibrillation ablation in the modern era?
thumbnail
Congress Presentation
Temporal patterns of atrial fibrillation recurrence after catheter ablation using pulsed-field ablation
thumbnail
Congress Presentation
Early recurrence predicts late recurrence in pulsed field ablation of atrial fibrillation even with modified blanking period: outcomes from a 1000-patient cohort

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources